One Product – Two Brands
Amendments proposed to be introduced to the Federal Law on Drug Circulation are being developed in the Ministry of Industry and Trade. According to these amendments it will be possible to manufacture similar drugs under different brands at the same site. According to the authors of the amendments, it will assist development of contract manufacture of drugs in Russia. According to the norms of today, the drugs manufactured at the same site under different trade names and under different brands, but with the same active substance, cannot be approved. If the amendments of the Ministry of Industry and Trade are accepted, local pharmaceutical companies will be able to manufacture at the same site both original drugs and generics under different brands. Besides, it will enable Russian manufacturers to produce drugs of other manufacturers. It will facilitate implementation of the import substitution program.
According to the experts amendments suggested by the Ministry of Industry and Trade will remove artificial barriers and will enable development of competition and reduction, although minor, of the final consumer price.